Clinical trials: Naloxone
Opioid-use Disorder
Improving Office Based Treatment of Opioid Use Disorder With Technology
The goal of this study is to evaluate whether using a novel drug-device combination to deliver buprenorphine/naloxone (B/N) to patients in office-based treatment for Opioid Use Disorder (OUD) is an effective way to improve…
- Trial name
- NCT03586466
- Testing
- BupreCare, Buprenorphine/naloxone, MEMS
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- MedicaSafe, Inc.
Chronic Pain, Opioid Induced Constipation
Naloxone SR Capsules in Patients With Opioid Induced Constipation
For many patients taking opioids for pain relief one of the most distressing side effects is constipation. Naloxone is effective in the reversal of the effects of opioids and is used following opioid overdose.
- Trial name
- NCT00984334
- Testing
- Naloxone SR 5 mg capsules, Naloxone SR 10 mg capsules, Naloxone SR 20mg capsules
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- S.L.A. Pharma AG
Upper Extremity Trauma
Effect of Ultra-low Dose Naloxone During Supraclavicular Brachial Plexus Block on Post-operative Opioi
Effective post-operative pain control can reduce patient morbidity and affect the patient outcome. Brachial plexus block is one of them, a popular and widely employed regional nerve block technique for perioperative anesthesia…
- Trial name
- NCT03372486
- Testing
- Bupivacaine plus naloxone, Bupivacaine
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Mansoura University
Heroin Dependence, Opioid-Related Disorders
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2
The purpose of this study is to compare the clinical efficacy of daily vs. 3-day (MWF) buprenorphine/naloxone combination tablet administration and determine whether outcomes are improved when using a 3-day schedule in which all…
- Trial name
- NCT00000327
- Testing
- Heroin Dependence
- Where
- United States
- Sponsor
- University of Colorado, Denver
Interstitial Cystitis, Painful Bladder Syndrome
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
The study compares the analgesic efficacy of OXN PR vs placebo in opioid-naive subjects suffering from severe pain due to Bladder Pain Syndrome.
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome, Pain
- Trial name
- NCT01197261
- Testing
- Oxycodone naloxone prolonged release tablets
- Where
- 5 sites in Czechia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Opioid-Related Disorders, Substance-Related Disorders
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
This pilot trial will explore the feasibility, acceptability, and effectiveness of the most recently approved formulation of injectable extended-release buprenorphine (XR-BUP) for treatment of opioid use disorder (OUD) in rural…
- Conditions
- Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
- Trial name
- RXR (NCT06023459)
- Testing
- Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone
- Where
- 7 sites in United States
- Volunteers
- 140 people
- Sponsor
- Yih-Ing Hser
Opioid-use Disorder
SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence
The purpose of this study is to compare the effectiveness of two different interventions for medication-assisted treatment (MAT) adherence: Contingency Management (CM) and Brief Motivational Interviewing + Substance Free…
- Trial name
- NCT04080180
- Testing
- Contingency Management, Brief Motivational Interviewing + Substance Free Activities + Mindfulness
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Karen Derefinko, PhD
Cocaine-related Disorders
Buprenorphine Naltrexone-P1 A-Cocaine
The purpose of this study is to determine if the opioid agonist effects of doses of 4/1 mg, 8/2 mg, and 16/4 mg of buprenorphine/naloxone can be completely blocked by 50 mg of oral naltrexone.
- Trial name
- NCT00733720
- Testing
- Suboxone
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders, Drug Overdose
Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients
REBOOT is a pilot randomized trial of a repeated-dose brief intervention to reduce overdose and risk behaviors among naloxone recipients (REBOOT).
- Trial name
- REBOOT (NCT02093559)
- Testing
- Brief counseling Intervention
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- San Francisco Department of Public Health
Healthy
The Effects of ∆-9-THC and Naloxone in Humans
The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.
- Trial name
- NCT01591629
- Testing
- Naloxone, Delta-9-THC
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Yale University
Gambling, Opioid
Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray
Non-controlled pilot study. Two groups: Group A: naloxone nasal spray max 8 mg/per day; Group B: naloxone max 16 mg/per day. Study duration 8 weeks. Brief intervention.
- Conditions
- Gambling, Opioid, Naloxone, Spray
- Trial name
- NALPILO (NCT03223896)
- Testing
- Naloxone hydrochloride 20mg/ml
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Opioid-Induced Constipation
Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation
Prospective, randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre, phase III trial of Naloxone HCl PR Tablets (12 mg and 24 mg) administered twice daily.
- Trial name
- Naxos (NCT03687268)
- Testing
- Naloxone HCl PR tablets
- Where
- 104 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 1,500 people
- Sponsor
- Develco Pharma Schweiz AG
Overdose, Risk Behavior
The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy
In the setting of naloxone standing orders, this study will assess if co-dispensing naloxone with opioids to patients prescribed chronic opioid therapy changes opioid risk behaviors, increases naloxone uptake, and increases…
- Trial name
- NCT03337100
- Testing
- Co-Dispensing
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Kaiser Permanente
Pain, Opioid Induced Constipation
Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives
The objective of the non-interventional study is to compare the quality of life, health care resource use and costs between the use of a combination of oxycodone and naloxone (Targiniq) versus oxycodone and laxatives for patients…
- Trial name
- NCT01812733
- Where
- Sweden
- Volunteers
- 37 people
- Sponsor
- Mundipharma AB
Pharmacodynamic
Pharmacodynamic Evaluation of Intranasal Nalmefene
This study is to determine the pharmacodynamics (the effects of the drug and mechanisms of their action within the body) of Nalmefene when given intranasally (IN; into the nose) compared to intranasal naloxone when given to…
- Trial name
- NCT04828005
- Testing
- Nalmefene hydrochloride, Naloxone hydrochloride
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Opiant Pharmaceuticals Inc
Opioid-Related Disorders
Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers
Buprenorphine, a treatment for opioid dependence, can be mixed with another drug, naloxone, to limit abuse potential. Parenteral administration (intravenous or intramuscular injection) of buprenorphine/naloxone causes withdrawal…
- Trial name
- NCT00134875
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Opioid Overdose
Risks and Benefits of Naloxone Prescribing
This investigation is one of the first large-scale, prospective attempts to obtain data on the effectiveness of naloxone distribution among opioid-abusing populations at high risk of unintentional opioid poisoning.
- Trial name
- NCT02535494
- Testing
- Extensive training
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- New York State Psychiatric Institute
Opioid Use Disorder
Development of an Opioid Withdrawal Clinical Outcome Assessment
Withdrawal management strategies are currently the most utilized and ubiquitous intervention for opioid use disorder in the US, yet existing measures of opioid withdrawal lack Food and Drug Administration (FDA) qualification.
- Trial name
- NCT07094672
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Heroin Dependence, Opioid-Related Disorders
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6
The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.
- Trial name
- NCT00000331
- Testing
- Test Drug
- Where
- United States
- Sponsor
- University of Colorado, Denver
Drug Overdose
Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use
Overdose with potential deadly outcome is a serious problem among opioid abusers, not least in Norway. The annual death toll from overdose is about 250, twice the annual death toll from traffic accidents.
- Trial name
- NCT02158117
- Testing
- nasal naloxone
- Where
- Norway
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology